New Zealand markets closed

Kiniksa Pharmaceuticals, Ltd. (KNSA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
20.19-0.07 (-0.35%)
At close: 04:00PM EDT
20.88 +0.69 (+3.42%)
After hours: 06:38PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.43B
Enterprise value 1.23B
Trailing P/E 155.31
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.83
Price/book (mrq)3.32
Enterprise value/revenue 4.08
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.32
52-week change 347.91%
S&P500 52-week change 326.43%
52-week high 322.09
52-week low 313.02
50-day moving average 319.15
200-day moving average 317.91

Share statistics

Avg vol (3-month) 3394.36k
Avg vol (10-day) 3404.4k
Shares outstanding 540.31M
Implied shares outstanding 671.19M
Float 821.41M
% held by insiders 14.22%
% held by institutions 190.52%
Shares short (15 Apr 2024) 43.64M
Short ratio (15 Apr 2024) 49.94
Short % of float (15 Apr 2024) 411.74%
Short % of shares outstanding (15 Apr 2024) 45.14%
Shares short (prior month 15 Mar 2024) 42.87M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 2.87%
Operating margin (ttm)-20.71%

Management effectiveness

Return on assets (ttm)-3.97%
Return on equity (ttm)2.11%

Income statement

Revenue (ttm)301.77M
Revenue per share (ttm)4.29
Quarterly revenue growth (yoy)65.20%
Gross profit (ttm)N/A
EBITDA -28.33M
Net income avi to common (ttm)8.65M
Diluted EPS (ttm)0.13
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)213.55M
Total cash per share (mrq)3.01
Total debt (mrq)12.14M
Total debt/equity (mrq)2.81%
Current ratio (mrq)4.21
Book value per share (mrq)6.10

Cash flow statement

Operating cash flow (ttm)21.55M
Levered free cash flow (ttm)26.97M